Literature DB >> 15087673

Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases.

Françoise Galateau-Sallé1, Jean Michel Vignaud, Louise Burke, Allen Gibbs, Elisabeth Brambilla, Richard Attanoos, Marcel Goldberg, Guy Launoy.   

Abstract

Well-differentiated papillary mesothelioma (WDPM) of the pleura represents a distinct mesothelial tumor presenting with unilateral pleural effusion and superficial spreading of stout papillary formations with myxoid cores, lined by bland, flattened, or epithelioid cells, without or with limited invasion of the submesothelial layer. The majority of cases have been reported in the peritoneum in women of reproductive age with no history of asbestos exposure and also in the tunica vaginalis of men. We report 24 cases of pleural WDPM and compared their histologic, epidemiologic, and clinical features with those of classic mesothelioma. Men and women were equally affected, with a mean age of 60 years. Half of the patients had a history of occupational asbestos exposure. In 11 patients with a minimal follow-up period of 24 months, the survival ranged from 36 to 180 months with an average of 74 months as compared with 9.89 months for 1248 paired patients with diffuse malignant mesothelioma. Ten-year survival was 30.8%. We conclude that WDPM is a rare and unusual mesothelial tumor, characterized by a lack of deep invasion and associated with an indolent clinical course and long survival. For these reasons, WDPM is best considered as a specific clinico-pathologic entity distinct from conventional diffuse malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15087673     DOI: 10.1097/00000478-200404000-00013

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

1.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

2.  Pathology of mesothelioma.

Authors:  Kouki Inai
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

3.  Malignant mesothelioma of the peritoneum: case reports and immunohistochemical findings including Ki-67 expression.

Authors:  Hiroshi Hirano; Takashi Fujisawa; Koichi Maekawa; Eriko Ohkubo; Akira Okimura; Kozo Kuribayashi; Takashi Nakano; Keiji Nakasho; Takashi Nishigami
Journal:  Med Mol Morphol       Date:  2010-03-26       Impact factor: 2.309

4.  My approach to the diagnosis of mesothelial lesions.

Authors:  K J Butnor
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

5.  The French National Mesothelioma Surveillance Program.

Authors:  M Goldberg; E Imbernon; P Rolland; A Gilg Soit Ilg; M Savès; A de Quillacq; C Frenay; S Chamming's; P Arveux; C Boutin; G Launoy; J C Pairon; P Astoul; F Galateau-Sallé; P Brochard
Journal:  Occup Environ Med       Date:  2006-02-09       Impact factor: 4.402

Review 6.  Mesothelioma of tunica vaginalis of "uncertain malignant potential" - an evolving concept: case report and review of the literature.

Authors:  Kiril Trpkov; Richard Barr; Andrew Kulaga; Asli Yilmaz
Journal:  Diagn Pathol       Date:  2011-08-25       Impact factor: 2.644

7.  Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42.

Authors:  Meredith Stevers; Joseph T Rabban; Karuna Garg; Jessica Van Ziffle; Courtney Onodera; James P Grenert; Iwei Yeh; Boris C Bastian; Charles Zaloudek; David A Solomon
Journal:  Mod Pathol       Date:  2018-08-31       Impact factor: 7.842

Review 8.  Current Management and Future Perspective in Pleural Mesothelioma.

Authors:  Rajiv Shah; Laura V Klotz; Julia Glade
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

9.  Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

Authors:  Saoirse O Dolly; Cristina Migali; Nina Tunariu; Chiara Della-Pepa; Shelize Khakoo; Steve Hazell; Johann S de Bono; Stanley B Kaye; Susana Banerjee
Journal:  ESMO Open       Date:  2017-04-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.